ConductScience.org, home

Paper39376992

Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response.

González MDR and 5 others. Front Oncol, 2024. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response. Papers, record 39376992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39376992

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Molecular profiling of pre- and post- 5-azacytidine myelodysplastic syndrome samples identifies predictors of response.
PubMed
Journal
Front Oncol
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.32, provisional
iCite
Revised in PubMed
2025-08-06
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1González MDRMónica Del Rey
2Chakraborty SSohini
3Hernández-Sánchez JMJesús María
4Diez Campelo MMaría
5Park CYChristopher Y
6Hernández Rivas JMJesús María

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 CA249054NCI NIH HHSUnited StatesR01CA249054PubMed

Source NIH RePORTER

Download CSV of grants

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119230772Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.Lancet Oncol2009https://conductscience.org/library/papers/19230772PubMed
224382349Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity.J Clin Invest2014https://conductscience.org/library/papers/24382349PubMed
328723562Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.Cell Rep2017https://conductscience.org/library/papers/28723562PubMed
4344488325-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice.Blood Adv2021https://conductscience.org/library/papers/34448832PubMed
527959731TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.N Engl J Med2016https://conductscience.org/library/papers/27959731PubMed
616778146Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells.Blood2006https://conductscience.org/library/papers/16778146PubMed
715793220FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.Oncologist2005https://conductscience.org/library/papers/15793220PubMed
820026804Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.J Clin Oncol2010https://conductscience.org/library/papers/20026804PubMed
927526324Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution.Nat Genet2016https://conductscience.org/library/papers/27526324PubMed
1020220779Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.Leukemia2010https://conductscience.org/library/papers/20220779PubMed
11322964395-Azacytidine Potentiates Anti-tumor Immunity in a Model of Pancreatic Ductal Adenocarcinoma.Front Immunol2020https://conductscience.org/library/papers/32296439PubMed
1216076868Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome.Blood2005https://conductscience.org/library/papers/16076868PubMed
1337422676Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review.Exp Hematol Oncol2023https://conductscience.org/library/papers/37422676PubMed
1418467609Myelodysplastic syndromes.Blood2008https://conductscience.org/library/papers/18467609PubMed
1527926740A 17-gene stemness score for rapid determination of risk in acute leukaemia.Nature2016https://conductscience.org/library/papers/27926740PubMed
1625943181Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.Leukemia2015https://conductscience.org/library/papers/25943181PubMed
1712011120Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.J Clin Oncol2002https://conductscience.org/library/papers/12011120PubMed
1823242597The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome.Haematologica2013https://conductscience.org/library/papers/23242597PubMed
1929214694Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Am J Hematol2018https://conductscience.org/library/papers/29214694PubMed
2022124213DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia.Leukemia2012https://conductscience.org/library/papers/22124213PubMed

See all 35 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42340493Predicting response to hypomethylating agents in myeloid neoplasms: a robust model.Ann Hematol2026https://conductscience.org/library/papers/42340493PubMed
42184718The silent pharmacist: Harnessing the gut microbiome to improve therapy in hematologic malignancies.Transl Oncol2026https://conductscience.org/library/papers/42184718PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD34947PubTator's text mininghttps://conductscience.org/library/genes/947NCBI Gene
MYC4609PubTator's text mininghttps://conductscience.org/library/genes/4609NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39376992

GET https://conductscience.org/api/papers/v1/39376992/references?page=2